52-Week Safety and Disease Control With Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From the Phase 3 TRuE-AD3 Study

By afschroeder • October 31, 2026

Paller AS, Stein Gold LF, Simpson EL, Zaenglein AL, Armstrong AW, Tollefson MM, Soong W, Lee LW, Devani AR, Forman SB, Siri DD, Kallender H, Angel B, Li Q, Purohit VS, Eichenfield LF. 52-Week Safety and Disease Control With Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From the Phase 3 TRuE-AD3 Study. J Am Acad Dermatol. 2026 Oct 30:S0190-9622(26)03835-1. doi: 10.1016/j.jaad.2026.10.072. Epub ahead of print. PMID: 42962926.

Tags: atopic dermatitis, children, Dermatology, disease control, eczema, JAK inhibitor, Janus kinase, pediatric, phase 3, Publications, randomized, ruxolitinib cream, safety, topical

Consistency of skin clearance with icotrokinra across patient subgroups with plaque psoriasis

Gold LS, Armstrong AW, Vender RB, Soung J, Pink AE, Cafone J, Edem BE, Reyes-Servin O, Jiang J, Cresswell K, DeKlotz CMC, Miller-Kassamali M, Yang[...]

Real-World Patient and Disease Characteristics, Treatment Outcomes and Satisfaction in Psoriasis: A Cross-Sectional and Retrospective Comparison of Advanced Therapies and Severities

Stein Gold L, Sofen HL, Siu K, Syeed S, Edson-Heredia E, Mitchell B, Goddard E, Kranz B, Gillespie-Akar L, Armstrong AW. Real-World Patient and Disease[...]

Case Report: Improvement in neurologic symptoms and remission following non-operative management of locally advanced cutaneous squamous cell carcinoma of the head and neck following cemiplimab therapy: two cases

Lee E, Samlowski W, Reynolds B, Sadrolashrafi K. Case Report: Improvement in neurologic symptoms and remission following non-operative management of locally advanced cutaneous squamous cell[...]